Orloff, G. M., Orloff, S. L., Kennedy, M. S., Maddon, P. J. & McDougal, J. S. Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry. J. Immunol. 146, 2578–2587 (1991).
Moore, J. P., Trkola, A. & Dragic, T. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9, 551–562 (1997).
Chan, D. C. & Kim, P. S. HIV entry and its inhibition. Cell 93, 681–684 (1998).
Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777–810 (2001).
Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690–698 (2008).
Ladinsky, M. S. et al. Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate. eLife 9, e58411 (2020).
Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302–1307 (1998).
LaBonte, J., Lebbos, J. & Kirkpatrick, P. Enfuvirtide. Nat. Rev. Drug Discov. 2, 345–346 (2003).
Miller, M. D. et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl Acad. Sci. Usa. 102, 14759–14764 (2005).
Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263–273 (1997).
Fernandes, J., Jayaraman, B. & Frankel, A. The HIV-1 Rev response element: an RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex. RNA Biol. 9, 6–11 (2012).
Bruun, T. U. J. et al. Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies. J. Biol. Chem. 299, 103062 (2023).
Luftig, M. A. et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody. Nat. Struct. Mol. Biol. 13, 740–747 (2006).
Gustchina, E. et al. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog. 6, e1001182 (2010).
Sabin, C. et al. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 6, e1001195 (2010).
Montefiori, D. C. et al. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat. Proc. Natl. Acad. Sci. USA 118, e2018027118 (2021).
Rubio, A. A. et al. A derivative of the D5 monoclonal antibody that targets the gp41 n-heptad repeat of HIV-1 with broad tier-2-neutralizing activity. J. Virol. 95, e02350-20 (2021).
Bell, B. N., Bruun, T. U. J., Friedland, N. & Kim, P. S. HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier. Proc. Natl. Acad. Sci. USA 120, e2215792120 (2023).
Groot, F., Welsch, S. & Sattentau, Q. J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111, 4660–4663 (2008).
Pope, M. & Haase, A. T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med 9, 847–852 (2003).
Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439–1452 (2010).
Pace, C. S. et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. USA 110, 13540–13545 (2013).
Sun, M. et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. JAIDS J. Acquired Immune Defic. Syndromes 66, 473–483 (2014).
Huang, Y. et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165, 1621–1631 (2016).
Moshoette, T., Ali, S. A., Papathanasopoulos, M. A. & Killick, M. A. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. Retrovirology 16, 31 (2019).
Moshoette, T., Papathanasopoulos, M. A. & Killick, M. A. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. Virol. J. 19, 143 (2022).
Jacobson, J. M. et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53, 450–457 (2009).
Klein, C. et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4, 653–663 (2012).
Tustian, A. D., Endicott, C., Adams, B., Mattila, J. & Bak, H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. mAbs 8, 828–838 (2016).
Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1. J. Virol. 72, 2855–2864 (1998).
Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. CP in Immunology 64, (2004).
deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489–2507 (2014).
Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. Usa. 105, 7552–7557 (2008).
Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. USA 110, 6626–6633 (2013).
Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med 384, 1003–1014 (2021).
Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455–461 (2014).
Pancera, M., Changela, A. & Kwong, P. D. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr. Opin. HIV AIDS 12, 229–240 (2017).
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J. Exp. Med. 185, 621–628 (1997).
Radford, C. E. et al. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Cell Host Microbe 31, 1200–1215.e9 (2023).
Simonich, C. A. et al. HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166, 77–87 (2016).
Wensing, A. M. et al. 2017 update of the drug resistance mutations in HIV-1.Top Antivir. Med. 24, 132–133 (2017).
Dingens, A. S., Arenz, D., Overbaugh, J. & Bloom, J. D. Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide. Viruses 11, 439 (2019).
Kitchen, S. G. et al. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 8, e1002649 (2012).
Perez, L. G., Costa, M. R., Todd, C. A., Haynes, B. F. & Montefiori, D. C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J. Virol. 83, 7397–7410 (2009).
Perez, L. G., Zolla-Pazner, S. & Montefiori, D. C. Antibody-dependent, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J. Virol. 87, 5287–5290 (2013).
Rujas, E. et al. Functional optimization of broadly neutralizing HIV-1 antibody 10E8 by promotion of membrane interactions. J. Virol. 92, e02249-17 (2018).
Irimia, A. et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog. 13, e1006212 (2017).
Kim, S., Filsinger Interrante, M. V. & Kim, P. S. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies. J. Virol. 97, e01647–22 (2023).
Nelson, J. D. et al. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377, 170–183 (2008).
Lee, J. H., Ozorowski, G. & Ward, A. B. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043–1048 (2016).
Carravilla, P. et al. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions. Nat. Commun. 10, 78 (2019).
Yang, S. et al. Dynamic HIV-1 spike motion creates vulnerability for its membrane-bound tripod to antibody attack. Nat. Commun. 13, 6393 (2022).
Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).
Sobieszczyk, M. E. et al. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. Lancet HIV 10, e653–e662 (2023).
Haddox, H. K., Dingens, A. S., Hilton, S. K., Overbaugh, J. & Bloom, J. D. Mapping mutational effects along the evolutionary landscape of HIV envelope. eLife 7, e34420 (2018).
Weidenbacher, P. A.-B. et al. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat. Chem. Biol. 18, 1270–1276 (2022).
Provine, N. M., Puryear, W. B., Wu, X., Overbaugh, J. & Haigwood, N. L. The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity. J. Virol. 83, 9002–9007 (2009).
Montefiori, D. C. Measuring HIV Neutralization in a Luciferase Reporter Gene Assay. in HIV Protocols (eds. Prasad, V. R. & Kalpana, G. V.) vol. 485 395–405 (Humana Press, 2009).
Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131–146 (2014).
Dadonaite, B. et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186, 1263–1278.e20 (2023).
Yu, T. C. et al. A biophysical model of viral escape from polyclonal antibodies. Virus Evolut. 8, veac110 (2022).
